Advertisement

Related Videos

Robin Feldman, JD: Are Dubious Patents a Large or Small Issue?

Charles Schiffer, MD, on Cost-Effective Use of Tyrosine Kinase Inhibitors for Chronic Myelogenous Leukemia

Mark J. Ratain, MD: The Justification for a Randomized Trial of Low-Dose Ibrutinib

Sarah Yim, MD, on Clinical Development of Biosimilars: Lessons for Interventional Pharmacoeconomics

David A. Hyman, MD, JD, on Inclusive Shared Savings

Advertisement

Advertisement




Nov
19
Today In Oncology
Newly Diagnosed AL Amyloidosis FDA Grants Traditional Approval to Regimen
New Computational Tool Shows Strong Accuracy in Predicting Cancer Drug Targets
Curative Treatment After First-Line Immunotherapy Improves Survival in HCC
Long-Term Survival With vs Without Postmastectomy Chest Wall Irradiation in Breast Cancer
FDA Approves Selumetinib for Adults With NF1 With Symptomatic, Inoperable Plexiform Neurofibromas
View More 
Advertisement
© 2025 HSP News Service, L.L.C.
Conexiant Oncology Logo